Drug Profile
Atrosab
Alternative Names: Anti-TNF-receptor-1 monoclonal antibody - Baliopharm; atrosab-MSLatest Information Update: 28 Dec 2023
Price :
$50
*
At a glance
- Originator Celonic
- Developer Baliopharm AG; Celonic
- Class Anti-inflammatories; Antirheumatics; Monoclonal antibodies; Neuroprotectants
- Mechanism of Action Type 1 tumour necrosis factor receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Inflammation; Multiple sclerosis; Rheumatoid arthritis
Most Recent Events
- 28 Dec 2023 No recent reports of development identified for phase-I development in Inflammation(In volunteers) in Germany (IV)
- 30 Dec 2021 Atrosab is still in phase-I development in Inflammation (In volunteers) in Germany (IV) (Baliopharm AG pipeline, December 2021)
- 28 Apr 2018 No recent reports of development identified for phase-I development in Inflammation(In volunteers) in Germany (IV)